Pfizer Recalls Nurtec ODT Prescription Drugs Due to Failure to Meet Child Resist...
Reason for Recall / Hazard
The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children.
Product Description & Identification
This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets. The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, expiration date. The dosage strength and expiration date are printed or stamped on the blister card. The recall includes the following: Product Description NDC Number Expiration Date Nurtec® ODT (rimegepant) 75mg 8-Unit Dose blister pack 72618-3000-2 All dates through 6/2026
Affected Products
Nurtec® ODT (rimegepant) orally disintegrating tablets, 75mg 8-Unit Dose blister pack
Additional Source Details
| Field | Value |
|---|---|
| U R L | https://www.cpsc.gov/Recalls/2023/Pfizer-Recalls-Nurtec-ODT-Prescription-Drugs-Due-to-Failure-to-Meet-Child-Resistant-Packaging-Requirement-Risk-of-Poisoning |
| Title | Pfizer Recalls Nurtec ODT Prescription Drugs Due to Failure to Meet Child Resistant Packaging Requirement; Risk of Poisoning |
| Images › 1 › U R L | https://www.cpsc.gov/s3fs-public/RecalledNurtecODTrimegepantorallydisintegratingtablets.jpg |
| Images › 1 › Caption | Recalled Nurtec® ODT (rimegepant) orally disintegrating tablets |
| Images › 2 › U R L | https://www.cpsc.gov/s3fs-public/RecalledNurtecODTrimegepantorallydisintegratingtabletsblisterpackaging.jpg |
| Images › 2 › Caption | Recalled Nurtec® ODT (rimegepant) orally disintegrating tablets (blister packaging) |
| Hazards › Name | The recalled prescription drugs must be in child resistant packaging as required by the Poison Prevention Packaging Act (PPPA). The packaging of the products is not child resistant, posing a risk of poisoning if the contents are swallowed by young children. |
| Injuries › Name | None reported |
| Products › Name | Nurtec® ODT (rimegepant) orally disintegrating tablets, 75mg 8-Unit Dose blister pack |
| Products › Number Of Units | About 4.2 million |
| Recall I D | 9565 |
| Remedies › Name | Consumers should immediately secure the recalled product out of the sight and reach of children and contact Pfizer for a free child resistant pouch to store the product. Once the product is secured, consumers can continue to use it as directed. |
| Retailers › Name | Pharmacies nationwide as a prescribed medicine from December 2021 through March 2023. The prices of the product varied based on health insurance terms and other factors. |
| Recall Date | 2023-03-16T00:00:00 |
| Description | This recall involves prescription drugs Nurtec ODT 75 mg orally disintegrating tablets sold in cartons containing one blister card of 8 tablets. The tablets are in a non-child resistant blister card packaged in a carton that includes the name of the product, dosage strength, expiration date. The dosage strength and expiration date are printed or stamped on the blister card. The recall includes the following: Product Description NDC Number Expiration Date Nurtec® ODT (rimegepant) 75mg 8-Unit Dose blister pack 72618-3000-2 All dates through 6/2026 |
| Recall Number | 23154 |
| Manufacturers › 1 › Name | Biohaven Pharmaceuticals Inc., of New Haven, Conn. |
| Manufacturers › 2 › Name | Pfizer Inc., of New York |
| Remedy Options › 1 › Option | New Instructions |
| Remedy Options › 2 › Option | Repair |
| Consumer Contact | Pfizer at 800-879-3477 Monday through Friday 9 a.m. to 7 p.m. ET, online at www.pfizer.com/contact or online at www.Nurtec.com/PackagingUpdate or www.Nurtec.com and click "Recall to provide child resistant pouches to patients for storage of their medicine. Click for details" for more information. |
| Last Publish Date | 2023-03-16T00:00:00 |
| Manufacturer Countries › Country | United States |
Overview
- Recalling FirmBiohaven Pharmaceuticals Inc., of New Haven, Conn., Pfizer Inc., of New York